Expression of the AF4-MLL fusion protein in murine hematopoietic progenitor/stem cells results in the development of proB acute lymphoblastic leukemia. In this study, we affinity purified the AF4-MLL and AF4 protein complexes to elucidate their function. We observed that the AF4 complex consists of 11 binding partners and exhibits positive transcription elongation factor b (P-TEFb)-mediated activation of promoter-arrested RNA polymerase (pol) II in conjunction with several chromatin-modifying activities. In contrast, the AF4-MLL complex consists of at least 16 constituents including P-TEFb kinase, H3K4 me3 and H3K79 me3 histone methyltransferases (HMT), a protein arginine N-methyltransferase and a histone acetyltransferase. These findings suggest that the AF4-MLL protein disturbs the fine-tuned activation cycle of promoter-arrested RNA Pol II and causes altered histone methylation signatures. Thus, we propose that these two processes are key to trigger cellular reprogramming that leads to the onset of acute leukemia.
Introduction
Chromosomal translocations of the human MLL gene are recurrently identified in acute leukemia patients. A total of 64 MLL chromosomal-fusion partners have been characterized so far at the molecular level, 1 all of which associated with the disease phenotype of either acute myeloid or acute lymphoblastic leukemia. Within the latter group, the fusion partners AF4, LAF4 and AF5q31 belong to the ALF protein family. 2 Of those, the chromosomal translocation t(4;11)(q21;q23) represents the most frequent genetic aberration of the MLL gene. This translocation results in the production of the two fusion proteins MLL-AF4 and AF4-MLL, respectively.
The pathomolecular mechanism of t(4;11)-mediated acute lymphoblastic leukemia is still controversial. B-cell lymphoma was developed by two transgenic animal model systems after long latency, but did not give rise to acute lymphoblastic leukemia. 3, 4 A recently established knock-in mouse model developed acute leukemia after Cre recombination of an Mll-AF4 stop allele. 5 The latter study proposed that extended H3K79 me2 signatures are associated with the process of leukemogenesis. By contrast, the reciprocal AF4-MLL fusion allele was shown to cause growth transformation in mammalian cells. 6 In addition, this study also revealed that the protein level of AF4 is regulated by E3-ubiquitin ligases binding to a motif localized in the N-terminal portion. Similarly, the AF4-MLL fusion protein is also a substrate for SIAH proteins. However, Taspase1-mediated hydrolysis 7 of AF4-MLL makes it resistant to proteasomal degradation. Moreover, transduction of murine hematopoietic progenitor/stem cells with a retrovirus encoding the AF4-MLL fusion protein resulted in development of proB acute lymphoblastic leukemia in mice. 8 Together, these findings imply that both t(4;11) fusion proteins, MLL-AF4 and AF4-MLL, contribute to the malignant processes in t(4;11) leukemia. Therefore, we decided to purify the AF4-MLL complex in order to gain insights into its pathological function.
Two other MLL fusion partner proteins, AF9 and ENL, both bind to the AF4 protein. Binding of AF9 was mapped to the C-terminal portion of AF4 (amino acids 766-779), 9 whereas ENL binds to a region encompassing amino acids 812-1049. 10 Furthermore, ENL interacts with AF10, DOT1L and histone H3.
11 DOT1L represents a unique H3K79 me2/3 histone methyltransferase (HMT) that marks the chromatin in actively transcribed regions. 12, 13 The N-terminal portion of AF4 family members binds to the CDK9/CCNT1 heterodimer, 14 which resembles the positive transcription elongation factor b (P-TEFb). 15 P-TEFb phosphorylates serine 2 residues within heptameric repeats of the carboxy-terminal domain (CTD) of RNA polymerase (pol) II. This leads to transcriptional elongation and allows binding of additional factors involved in RNA splicing and transcriptional termination.
In this study, we report the successful purification and functional characterization of the AF4 and AF4-MLL protein complexes. AF4 resembles an activator of RNA Pol II and leads to transcriptional elongation, as recently postulated for murine AF4. 16 In contrast, the AF4-MLL complex exhibits a different composition of HMT and histone acetyltransferase activities and displays a much higher P-TEFb kinase activity when compared with the AF4 complex. These findings suggest that AF4-MLL alters transcriptional processes and epigenetic signatures in a genomewide manner. On the basis of our data, we propose that both mechanisms are key processes in MLL-mediated leukemia development.
Materials and methods

Expression plasmids, cell culture and transfection experiments
Complementry DNAs coding for AF4, FelC and AF4-MLL were cloned into pTarget (Promega, Mannheim, Germany) or pEXPR-IBA103 (IBA GmbH, Göttingen, Germany). Adherent 293T or HeLa cells were maintained in Dulbecco's modified Eagle's medium (PAA) supplemented with 10% FCS and antibiotics. Cells were transfected either using the Polyethylenimine (Sigma) or the Ca 2 þ phosphate precipitation method. Generally, 2.5 Â 10 7 cells were transfected with 25 mg of each plasmid.
Size exclusion chromatography
A 500 ml sample was prepared with IP buffer (150 mM NaCl, 20 mM HEPES, pH 7.5, 1% Triton X-100, 1 mM Na 3 VO 4 , 10 mM NaF, 1 mM PMSF, 1 Â Protease Inhibitor Cocktail V, EDTA free) from 1.5 Â 10 8 transient transfected cells and subjected to size-exclusion chromatography by using a Sepharose-6 10/300 column controlled by an AKTA-FPLC system (GE Healthcare, Munich, Germany). Protein complexes were separated by their molecular weight in a buffer containing 1 Â PBS/1 mM DTT at a constant flow rate of 0.3 ml/min. Standard proteins were spiked and used to evaluate the size of the protein complexes (Gel Filtration HMW Calibration Kit, GE Healthcare). Western blots were performed to identify elution fractions that contain the appropriate protein complexes.
Affinity purification of AF4 and AF4-MLL
For protein complex purification, 1 Â 10 9 transient transfected 293T cells were lysed 48 h after transfection in IP buffer (see above). Proteasomal degradation of these proteins was prevented by adding 5 mM MG132 (Calbiochem, Darmstadt, Germany) 16 h before lysis. Affinity purification was performed by a centrifugation step (4 1C for 30 min at 14 000 Â g) to obtain a cleared supernatant, which was then incubated with Avidin before the lysate was loaded onto SuperFlow Streptactin columns (IBA GmbH). All procedures were performed according to the manufactures instructions.
Proteolytic digestion and nLC-MALDI MS/MS
For in-solution digests, 60 ml of each elution sample was concentrated by using vivaspin 500 centrifugal concentrator (Sartorius, Gö ttingen, Germany) in 25 mM NH 4 HCO 3 (pH 8.0). Samples were treated with 10 mM DTT/25 mM NH 4 HCO 3 and 50 mM iodoacetamide/25 mM NH 4 HCO 3 , and proteolytic digests were carried out by adding 0.5 mg trypsine (Sigma) and incubated for 24 h at 37 1C. Digestion was stopped by adding 1 ml formic acid. A reverse-phase high performance liquid chromatography was performed on an Easy liquid chromatography (LC) from Proxeon (Odense, Denmark). The separation was carried out on a PepMap 100 (0.075 Â 150 mm; 5 mm particles; C-18 column; Dionex) with a flow rate of 300 nl/min. MALDI-MS-MS/MS instrument configuration and data acquisition was carried out as described previously. 17 MS/MS peak lists from three to six replicate runs were used for queries of the MASCOT database (Matrix Science Ltd., London, UK). 18 All nLC MS/MS data are summarized in Supplementary Table S1 .
Western blot experiments
Purified protein complexes were analyzed by western blot by using the monoclonal mouse antibody 6E95 (anti-AF4-N). 6 Transferred proteins were visualized with the ECL detection system (GE Healthcare). The following monoclonal antibodies were used: anti-NPM1, -RNA pol II-CTD, -E2F4, -E2F6, -GADD34, -RBBP5, -NFkB/p65, -Ash2L, -WDR5, -CBP, -RING1, -RING2, -HCFC2, -HIP2, -HEXIM1, -NSD1, -CARM1, -DOT1L and -INI1/SMARCB1 antibodies were obtained from Abcam, Cambridge, UK; anti-CDK9, -Cyclin T1, -Brd4 N17 , -MOF1, -NSD1 and -HCFC1 antbodies were obtained from Santa Cruz Biotechnologies, Heidelberg, Germany; anti-AF9, -AF10, -ENL, -DOT1L and -PC3 antibodies were obtained from Abgent (Oxfordshire, UK).
Immunoprecipitation experiments
Non-and transfected 293T cells (1.5 Â 10 8 cells) were resuspended in 0.6 ml IP buffer (see above), and after lysis at 4 1C cells were centrifuged for 30 min at 4 1C with 14 000 Â g. The supernatant was incubated with 50 ml Protein G agarose beads (Sigma) for 30 min at 4 1C. Beads were pelleted and the supernatant was incubated with 5-10 ml of concentrated antibody solution for 1 h at room temperature, and then overnight at 4 1C. After adding 60 ml protein G agarose beads for 3 h at 4 1C, the precipitated fraction was washed five times with 500 ml PBS buffer, followed by short centrifugation steps (800 r.p.m. ¼ 60 Â g for 10 s). Immunoprecipitates were then separated on sodium dodecyl sulfate-PAGE (SDS-PAGE).
In vitro histone methylation experiments
In vitro HMTase assays were performed as described previously. 19 Briefly, purified AF4 and AF4-MLL protein complexes (amounts equivalent to 1-5 Â 10 7 cells) were co-incubated either with a recombinant 3 mg GST-H3 (amino acid 1-46) fusion protein or with 15 mg purified-chicken histones (Upstate) and 1 mCi 
Chromatin fluorescence-activated cell sorting (FACS) experiments
293T cells were transiently transfected with an MLL-AF4, AF4-MLL, AF4-MLL::GFP fusion plasmid using AMAXA protocols and cell line nucleofector kit V. Untagged expression constructs were co-transfected with EGFP-expressing pMAX vector. At 2 days post transfection, cell samples were harvested and 250 000 cells were used for each staining sample. Before performing intra-nuclear staining cells were fixed/permeabilised with 88% ice-cold methanol, then cells were incubated with H3-, H3K4 me3 -or H3K79 me3 -specific primary antibodies as recently described. 20 After washing cells were incubated with APC-conjugated secondary antibody (Dianova, Hamburg, Germany). Cells were analyzed on a fluorescence-activated cell sorting (FACS) Canto flow cytometer using FACS Diva (BD Biosciences, Heidelberg, Germany) software. Cells in the life cell gate that were EGFP þ were electronically gated and histone H3-, histone H3K4 me3 -and H3K79 me3 -specific fluorescence profiles were recorded. Gates were set according to unstained or untransfected control samples. All experiments have been repeated three times in independent replicates and Student's ttest (one-tailed) was used for statistical analysis.
In vitro phosphorylation experiments
In vitro phosphorylation experiments were carried out with affinity purified AF4 and AF4-MLL complexes and a recombinant 6xHis-GST-[YSPTSPS] 2x substrate protein. Incubations
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A Benedikt et al were carried out in a buffer containing 100 mM Tris/HCl pH8, 150 mM NaCl, 1 mM EDTA, 2 mM DTT, 5 mM MgCl 2 and 1 mM ATP. As control, we used affinity purifications of mock-or untransfected cells. A 6xHis-GST protein served as negative control. DRB (5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole; 10 mM) and Flavopiridol (100 nM) were used to block P-TEFb activity. Western blot experiments were performed with antibodies specifically binding to P-serine-2/5 of the canonical [YSPTSPS]-repeat of RNA poly II CTD, to CDK9 and to acetyllysine residues.
HIV-TAR-Luciferase reporter assays
293T cells were concomitantly transfected with a HIV-TARLuciferase reporter construct 21 , and either empty vector, AF4 or AF4-MLL together with 20 pg of internal control vector (Renilla-Luc). All measurements were performed without TAT protein or (12-O-tetradecanoylphorbol-13-acetate) TPA-treatment to concentrate on the effects provided by AF4 and AF4-MLL on promoter-arrested RNA pol II. After 24 h, cells were harvested and Luciferase assays were performed. Quantitative western blotting was performed from transfected cells by using the Odyssey Imaging System (LI-COR Biosciences, Bad Homburg, Germany) according to the recommendations of the manufacturer. Fold activation was then calculated on the basis of measured Luciferase activity in correlation with the protein amount present in the transfected cells (AF4 w/o MG132 was set to 1).
Results
Size exclusion chromatography of AF4 and AF4-MLL protein complexes
To assess the ability of AF4 and AF4-MLL to form high molecular weight complexes, size exclusion chromatography experiments were performed. Strep-tagged AF4 and AF4-MLL proteins were isolated from transfected 293T cells and aliquots were separated on a Sepharose-6 10/300 column. As shown in Figure 1a (upper panel), the AF4 complex was predominantly identified in fractions eight and nine, with a predicted molecular mass of about 2 MDa. Bands below 175 kDa represent degradation products (verified by peptide mass fingerprinting) that are still recognized by the AF4-N antibody. Taspase1 cleavage of AF4-MLL results in p178 N-(AF4-MLL K N) and p134 C-terminal protein fragments (MLL K C). Cleaved AF4-MLL K N fragments were found in fractions 8-13 ( Figure 1b, lower panel) , suggesting complexes with a molecular weight of 1-2 MDa. This indicated that AF4 and AF4-MLL are both able to assemble into high molecular weight complexes.
Affinity purification of the human AF4 and AF4-MLL protein complexes
Strep-tag purification of both protein complexes was carried following transfection into 293T cells after treatment with MG132. After cell lysis, strep-tagged AF4 or AF4-MLL protein was eluted from affinity columns and separated on gradient SDS-PAGE. For all experiments, an empty strep-tag vector was transfected and analyzed in parallel (pEXPR-IBA103 ¼ mock). A representative gradient acrylamide gel is shown for AF4 and AF4-MLL in Figure 1b (upper and lower panel, respectively) . Purification of both protein complexes has been carried out at least 30 times and only consistent data are presented.
Composition of the AF4 and AF4-MLL protein complex
To analyze the composition of affinity-purified AF4 and AF4-MLL protein complexes, two approaches were applied. First, purified-protein complexes were digested by Trypsin and subsequently analyzed by nano liquid chromatography in combination with mass spectrometry (nLC-MS/MS; Supplementary Table S1 ). Second, a series of western blot experiments was performed using antibodies against predicted binding partners which were retrieved from the BIOGRID 22 and the STRINGS database. 23 By applying both approaches, we were able to unravel the binding partners of both protein complexes (Figures  2a and b) . We also purified a strep-tagged FelC protein, a natural protein variant comprising AF4 amino acids 1-389 (data not shown). 2, 6 This allowed the identification of proteins that bind solely the N-terminal portion of AF4.
On the basis of these data, we conclude that the N-terminal portion of AF4 binds to P-TEFb. Other constituents were BRD4, NFkB1/RELA, NPM1 and HEXIM1. The C-terminal portion of AF4 binds to ENL, less to AF9, AF10 and DOT1L. Additional proteins were DDX6 and AF5, as demonstrated by nLC-MS/MS experiments. Binding of CCNT1, NFkB1, DDX6 and HEXIM1 was validated by co-immunoprecipitation experiments Fwere both fused to GFP. This was necessary because wild-type BRD4 migrates in the SDS-PAGE at a similar position as AF4. As summarized in Figure 2c (panels V and VI), NPM1 and BRD4 are both part to the AF4 complex. Moreover, the purified FelC protein displayed only homodimerization activity for AF4 and AF4-MLL, indicating that the heterodimerization domain for AF5 is located in C-terminal portion of AF4.
The AF4-MLL fusion protein is composed of AF4 (346 amino acids) and MLL protein sequences (2563 amino acids). Therefore, we focused our work on proteins known to interact with both wild-type protein complexes. Binding of CCNT1, CDK9, NFkB1/RELA, NPM1, DDX6 (weakly) and HEXIM1 was confirmed either by western blot (Figure 2b ) or co-IP experiments (Figure 2c ). We also confirmed binding of HCFC1, HCFC2, CREBBP and proteins of the SET domain complex (WDR5, ASH2L, RBBP5 and DPY30). 25 Interestingly, nLC-MS/MS experiments revealed the presence of 23 C-terminal peptides of AF4, indicating that a full-length AF4 protein must be present within the AF4-MLL complex, wheras the presence of AF5 or BRD4 could not be verified (Figure 2c Both purified protein complexes reveal in vitro histone methyltransferase activity Next, we addressed functional aspects of both purified protein complexes by probing for HMT activity. Either a recombinant GST-H3 (amino acid 1-46) fusion protein or commercially available chicken core histone particles were incubated with affinity-purified complexes of AF4 or AF4-MLL and 3 H-labeled S-adenosylmethionine. Again, a strep-tag affinity purification of mock-transfected cells served as a negative control. After SDS-PAGE separation 3 H-labeled methylgroup transfer onto histone H3-peptide or -protein was observed (Figures 3a and b) . Unexpectedly, the affinity-purified AF4 protein complex also methylated the GST-H3 fusion protein, although no lysine-79 residue was present. This indicated that an unidentified HMT was present in the purified-AF4 complex. Therefore, we tested for the presence of other HMTs that could explain the observed methylation activity. In subsequent experiments we were able to demonstrate that endogenous NSD1 binds to the AF4 complex (Figure 3c ), which may confer H3K36 and H4K20 HMT activity. Moreover, endogenous CARM1/PRMT4 and DOT1L were both bound to AF4 and AF4-MLL, indicating that they are integral 
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A Benedikt et al parts of both protein complexes (Figure 3c) . Thus, the combined results of recombinant histone methylation and co-immunoprecipitation experiments predict that the AF4 complex is per se able to exhibit H3K36, H3K79, H4K20, H3R2, H3R17 and H3R26 HMT activities, whereas the AF4-MLL complex exhibits H3K4, H3K79, H3R2, H3R17 and H3R26 HMT activities in conjuction with the CREBBP-associated histone acetyltransferase activity.
AF4-MLL expression causes global changes in histone H3 methylation signatures
To analyze the consequences of t(4;11) fusion protein expression on H3K4 and H3K79 histone methylation, transient transfection experiments in 293T cells were carried out by using either an MLL-AF4, AF4-MLL or AF4-MLL::GFP expression plasmid. Global histone methylation levels were analyzed by chromatin FACS analyses. 20 At 2 days post transfection, fixed and permeabilized cells were simultaneously stained for histone H3 and H3K4 me3 or H3 and H3K79 me3 . H3-normalized H3K4 me3 or H3K79 me3 levels in untransfected cells were set to 100%. Figure 4b displays the increase of mock-normalized global H3K4 me3 levels in cells that were transfected with AF4-MLL::GFP or pMAX/AF4-MLL. Similarly, global H3K79 me3 levels increased in cells that were transiently transfected with AF4-MLL::GFP or pMAX/MLL-AF4. These results indicate that MLL-AF4 and AF4-MLL share an H3K79 me3 HMT activity, whereas the AF4-MLL complex exerts additionally H3K4 me3 HMT activity.
In vitro phosphorylation of GST-CTD by P-TEFb kinase of both the purified complexes Next, we investigated the effects of AF4 and AF4-MLL on RNA pol II. For this purpose, a GST-[YSPTSPS] 2x substrate protein was cloned and incubated with the affinity-purified AF4 or AF4-MLL protein complexes. Specific antibodies raised against CDK9, CTD phospho-serine 2/5 and acetyl-lysine demonstrated that both purified complexes exhibit in vitro P-TEFb kinase activity (Figure 5a ). However, AF4-MLL seems to exhibit a stronger CDK9 kinase activity, presumably because of a higher level of acetylation. Thus, we repeated these experiments by diluting the AF4-MLL complexes until equal amounts of CDK9 were observed in western blots (Figure 5b, upper panel) . Under these conditions (B50-fold more AF4 than AF4-MLL), no higher P-TEFb kinase actvity and no stronger acetylation signals were observed. P-TEFb kinases activity of both complexes could only be slightly inhibited by DRB (Figure 5b, middle panel) , while Flavopiridol affected more the AF4-than the AF4-MLLassociated P-TEFb kinase (Figure 5b, lower panel) . As shown in Figure 5c , transient expression of AF4 or AF4-MLL resulted in HEXIM1 increase (B2-fold). Increased HEXIM1 reflects increased P-TEFb kinase activity. 31 Thus, strongly overexpressed AF4 or tiny amounts of AF4-MLL had similar effects, indicating that latter fusion protein functions like a dominant-positive variant of the AF4 complex.
We also performed reporter assays using a HIV1-TARLuciferase reporter gene (see Figure 5d) . All experiments were carried without the addition of TAT protein or TPA-stimulation (increases SP1 and NFkB1) in order to measure the direct effects of AF4 and AF4-MLL on arrested RNA pol II. Co-transfection experiments of the reporter plasmid in combination with mock, AF4 or AF4-MLL revealed their transactivation activity. The addition of MG132 produced even higher readouts in mocktransfected cells, because endogenous AF4 becomes stabilized against proteasomal degradation. This effect was not expected for AF4-MLL, because (1) Taspase1-cleavaged AF4-MLL becomes resistant against proteasomal degradation, and (2) recombinant AF4-MLL is competing for factors bound to the endogenous AF4 complex. To circumvent this problem, reporter gene activation was correlated to the amount of recombinant protein measured by quantitative western blotting. Subsequent calculations revealed that AF4 ( ± MG132) and AF4-MLL (±MG132) are both able to activate the reporter gene (7-and 18-fold, respectively). Thus, AF4 and AF4-MLL are both able to trans-activate promoter-arrested RNA polymerase even in the absence of any physiological signal.
Discussion
Human AF4 and AF4-MLL fusion protein complexes were purified to understand their physiological and pathological roles. In consideration of recent findings, 10 the C-terminal portion of AF4 binds to ENL, AF10 and DOT1L, while the N-terminal portion of AF4 binds to P-TEFb kinase, BRD4 (binding directly to CCNT1) and NFkB1/RELA (binding directly to CCNT1, BRD4, NPM1 and CARM1). NFkB1/RELA and NPM1 are both binding directly to HEXIM1. Whether NSD1 binds directly to AF4 or to other binding proteins is yet not clear. NSD1 is the only known HMT that is able to methylate residues of histone H3 (K36) and H4 (K20). CARM1 is a protein arginine N-methyltransferase that has specificity for R2, R17 and R26 of histone H3. CARM1 has been described as transcriptional activator that directly interacts with NFkB1/RELA and CREBBP. 
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Binding of the AF4 complex to promoter proximal-arrested RNA pol II (POL O) initiates the conversion into elongating RNA pol II (POL E). During this process, DOT1L confers H3K79 methylation within the transcribed area. AF5 is a part of the AF4 complex and the first family member demonstrated to bind to P-TEFb.
14 Bound BRD4 stimulates the P-TEFb kinase function, facilitates binding of the AF4 complex to chromatin and prevents binding of HEXIM1. 24, 33 Of interest, BRD4 binds to the acetylated NFkB1/RELA (K310) and functions as specific co-activator of NFkB1/RELA to regulate transcription of a subset of NFkB1-responsive inflammatory genes 34 , and has been described as binding partner of NPM1. NFkB1/NPM1 heterodimers 
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A Benedikt et al influence binding of NFkB1, E2F1 and pRB to the E2F1 promoter. 35 Interestingly, NPM1 binds to HEXIM1 and mediates its proteasomal degradation, and thus, positively influences P-TEFb kinase activity. 36 The AF4-MLL protein complex is composed of AF4-MLL, AF4 and 15 other binding partners. As all indentified binding partners belong either to AF4 or MLL, [37] [38] [39] it may argue for a competitive situation between AF4-MLL fusion protein and both wild-type complexes. Binding of P-TEFb, NFkB1/RELA, NPM1, CARM1 and DOT1L to the N-terminus of AF4-MLL fusion protein allows a direct interaction with RNA pol II and to convert promoter-arrested RNA Pol II into the elongating state. Although we excluded binding of BRD4 to the AF4-MLL complex, the in vitro phosphorylation experiments revealed Characterization of the oncogenic AF4-MLL complex A Benedikt et al highly activated P-TEFb kinase (Figures 5a and b) . Missing BRD4 protein could be functionally compensated by a high acetylation level of CDK9 lysine 44, most likely deriving from the associated CREBBP protein. Because of a negative feed-back loop, 31 the level of HEXIM1 increased in the presence of AF4 or AF4-MLL (Figure 5c ).
At the C-terminus of AF4-MLL, the assembly of a functional SET-domain complex (HCFC1, HCFC2, WDR5, RBBP5, ASHL2 and DPY30) was verified in western blot experiments. As shown in Figure 4b , the presence of AF4-MLL increased H3K4 me3 methylation patterns (22-31%), while elevated H3K79 me3 signatures were similar in AF4-MLL-or MLL-AF4-transfected cells. In line with published data, 5 proposing that ectopic H3K79 methylation patterns are responsible for the development of acute leukemia, we have to conclude that the AF4-MLL fusion protein is capable of changing epigenetic signatures. Bound CARM1 and CREBBP protein may even augment the positive effects on transcription. In conclusion, AF4-MLL function on RNA pol II like a dominant-positive and nondegradable version of the AF4 protein. In addition, CARM1 has been described as co-activator of NFkB1/p65 and directly interacts with CREBBP. 32, 40 On the basis of these data, we propose a model for the functions of the characterized AF4 and AF4-MLL protein complexes. As depicted in Figure 6a , MLL and AF4 protein complexes are both involved in the activation of promoter Chromatin modifications mediated by the MLL complex lead to the activation of promoter regions. MEN1-associated proteins like for example, LEDGF and cMYB are not shown. The MLL complex exerts H3K4 me (SET-domain complex), H4K16 Ac (MOF), general histone acetyltransferase activity (CREBBP) and mono-ubiquitinylation of H2AK119 (BMI1). The AF4 complex activates RNA Pol II by CTD-P, DSIF-P and NELF-destruction by phosphorylation (P-TEFb). DOT1L, NSD1 and CARM1 modify the chromatin during the elongation state of RNA Pol II. (b) The AF4 complex exerts three independent chromatin-modifying functions. Active P-TEFb phosphorylates serine 2 of the hepatmeric peptide sequence [YSPTSPS] . PTEF-b kinase is also important for the activation of UBE2A and DSIF, whereas NELF gets destroyed after phosphorylation. Phosphorylated UBE2A associates with RNF20/40 and mono-ubiquitinylates histone H2B lysine 123 residues in histone core particles. The associated HMT NSD1 methylates H3K36. The HMTs DOT1 and CARM1 are able to methylate H3K79 and H3R2, R17 and R26, respectively. All these chromatin signatures enhance transcriptional processes. (c) The AF4-MLL fusion protein concomitantly exerts functions of AF4 and MLL, thereby changing chromatin properties. CREBBP activates P-TEFb by K44-Acetylation (in the absence of BRD4), which results in ectopic activation of promoter-arrested RNA Pol II. The functions of the SET-domain complex, DOT1L and CARM1 result in chromatin signatures that confer active chromatin to enhance transcriptional processes.
A Benedikt et al regions and promoter-associated RNA pol II. Thus, initiation and elongation of transcriptional processes requires the concomitant binding of both protein complexes. The AF4 complex provides several activities that could activate RNA pol II in subsequent steps (Figure 6b ). By contrast, the presence of the AF4-MLL fusion protein complex seems to activate transcription in an autonomous manner (Figure 6c ), because it exerts crucial properties of both parental protein complexes (active P-TEFb kinase and histone-modifying properties). This should enhance transcriptional processes and finally leadFbecause of unphysiological chromatin signatures (H3K4, H3K79, H3R2, H3R17, H3R26 and histone acetyltransferase)Fto epigenetic changes in transcribed chromatin regions. An extended H3K4 me3 signature may even cause the activation of neighboring gene regions, and thus, could probably reactivate already inactivated chromatin sections. This notion is supported by the observed changes in gene transcription after short-term expression of AF4-MLL fusion protein. 41 Of interest, different complexes seem to be formed by AF4 family members, like for example, the recently described AF5 complex which contained AF4, ENL, AF10, DOT1L, AF6, AF17 and several ELL's. 42 We have not identified AF6, AF17 or ELL1-3 in our purified complexes (data not shown), suggesting that cells are able to form different complexes by AF4 family members that exert, however, highly similar functions. 43, 44 In conclusion, the purification and characterization of AF4 and AF4-MLL extends very much our current knowledge and explains the functional consequences of expressed AF4-MLL fusion protein. Further studies to dissect the protein interaction network within the AF4 and AF4-MLL complexes are currently underway. However, protein interaction databases already predict additional interactions with other cellular proteins that we have not investigated in this study. These potential interactions are depicted in Supplementary Figure S1 , indicating that we have only started to understand the molecular consequences of expressed MLL fusion proteins in leukemia cells.
